US 10,441,611 B2 · Method for producing amniotic mesenchymal stromal cell composition, method for cryopreserving the same, and therapeutic agent

Method for producing amniotic mesenchymal stromal cell composition, method for cryopreserving the same, and therapeutic agent

AssigneesNational Cerebral and Cardiovascular Center, Foundation for Biomedical Research and Innovation At Kobe, Hyogo College of Medicine, National University Corporation Hokkaido University, Kaneka Corporation

InventorsKenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi

Life of this patent

Estimating the term…

Abstract

An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Claims13

Dependent claims

A method for producing cultured mesenchymal stromal cells, the method comprising:

preparing a mixture of mesenchymal stromal cells and a solution, wherein the mesenchymal stromal cells are mesenchymal stromal stern cells contained in a mesenchymal stromal cell composition;
cryopreserving the mixture;
thawing the cryopreserved mixture;
and
culturing the thawed mixture, thereby obtaining the cultured mesenchymal stromal cells,
wherein the mesenchymal stromal cell composition comprises 20% or less of CD324-positive epithelial cells and 75% or more of CD90-positive cells,
wherein the solution comprises from 5% to 10% by mass of dimethylsulfoxide, and from 5% to 10% by mass of hydroxyethyl starch or from 1% to 5% by mass of dextran.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/912,662Filed 18 Aug 2014

Priority

JP 2013-17000819 Aug 2013

Published

US 2016/0228474 A111 Aug 2016

Granted

15 Oct 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 35/50
Reproductive organs: placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 35/28
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61L 27/3834
Characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells: cells able to produce different…